Holen Sie sich die Stockscreener-App
22.34
7.44%
1.51
Schlusskurs vom Vortag:
$20.83
Offen:
$20.84
24-Stunden-Volumen:
177.30K
Relative Volume:
0.71
Marktkapitalisierung:
$246.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-74.14M
KGV:
-1.9614
EPS:
-11.39
Netto-Cashflow:
$-65.70M
1W Leistung:
-21.56%
1M Leistung:
-16.96%
6M Leistung:
+17.23%
1J Leistung:
+117.28%
1-Tages-Spanne:
$20.60
$22.49
1-Wochen-Bereich:
$20.60
$29.80
52-Wochen-Spanne:
$9.6201
$92.00
Instil Bio Inc Stock (TIL) Company Profile
Firmenname
Instil Bio Inc
Sektor
Branche
Telefon
(972) 499-3350
Adresse
3963 MAPLE AVENUE, DALLAS
Vergleichen Sie TIL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TIL
Instil Bio Inc
|
22.39 | 246.42M | 0 | -74.14M | -65.70M | -11.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.05 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
541.48 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.45 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.07 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.74 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Instil Bio Inc Stock (TIL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Perform |
| 2024-04-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-11-01 | Herabstufung | Truist | Buy → Hold |
| 2021-08-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-04-13 | Eingeleitet | Cowen | Outperform |
| 2021-04-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-04-13 | Eingeleitet | Truist | Buy |
Alle ansehen
Instil Bio Inc Aktie (TIL) Neueste Nachrichten
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet - MSN
Instil Bio (TIL) Enhances Axion Bio Board with New Appointment | - GuruFocus
Instil Bio Names John Maraganore, Ph.D., to Board Role - GlobeNewswire
Instil Bio Names John Maraganore, Ph.D., To Board - citybiz
Instil Bio, Inc. Announces the Addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Inc., Its Wholly-Owned Subsidiary - MarketScreener
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program - Yahoo Finance
(TIL) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Instil Bio Appoints ‘Seasoned’ Biopharma Exec as Chief Medical Officer - Dallas Innovates
H.C. Wainwright reiterates Instil Bio stock Buy rating amid partnership news By Investing.com - Investing.com South Africa
Instil Bio (TIL) Receives Reiterated Buy Rating from HC Wainwrig - GuruFocus
H.C. Wainwright reiterates Instil Bio stock Buy rating amid partnership news - Investing.com Canada
Instil Bio (TIL) Receives Reiterated Buy Rating from HC Wainwright & Co. | TIL Stock News - GuruFocus
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice - Yahoo Finance
Instil Bio appoints new Chief Medical Officer By Investing.com - Investing.com South Africa
Instil Bio (TIL) Rating Reiterated as Market Perform by JMP Secu - GuruFocus
Instil Bio (TIL) Rating Reiterated as Market Perform by JMP Securities | TIL Stock News - GuruFocus
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire
Instil Bio (TIL) Appoints Jamie Freedman as Chief Medical Officer - GuruFocus
Instil Bio (TIL) Appoints Jamie Freedman as Chief Medical Officer | TIL Stock News - GuruFocus
Instil Bio appoints new Chief Medical Officer - Investing.com
Former Genentech Executive With 15 FDA Approvals Joins Instil Bio to Accelerate Cancer Drug Development - Stock Titan
Instil Bio shares hold as JMP reiterates Market Perform rating By Investing.com - Investing.com India
Instil Bio shares hold as JMP reiterates Market Perform rating - Investing.com Australia
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade - MSN
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference - The Manila Times
Instil Bio CEO Reveals Latest Pipeline Updates at Prestigious Jefferies Healthcare Conference - Stock Titan
Instil Bio Elects Director and Ratifies Auditor - TipRanks
What's Behind The Big Stock Moves? SPRO, TIL, IMAB.... - Nasdaq
Instil Bio Advances Phase 2 Trial in China - TipRanks
(TIL) Proactive Strategies - news.stocktradersdaily.com
Instil Bio: Second Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success (TIL) - Seeking Alpha
H.C. Wainwright lifts Instil Bio stock target to $125 By Investing.com - Investing.com South Africa
H.C. Wainwright lifts Instil Bio stock target to $125 - Investing.com
Instil Bio (TIL) Receives Price Target Upgrade by HC Wainwright & Co. | TIL Stock News - GuruFocus
H.C. Wainwright Boosts Instil Bio (TIL) Price Target Following P - GuruFocus
Instil Bio and ImmuneOnco to Host Investor and Analyst - GlobeNewswire
Instil Bio and ImmuneOnco Announce Joint Investor Breakfast in Chicago to Discuss Immuno-Oncology Developments - Nasdaq
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving ... - Bluefield Daily Telegraph
H.C. Wainwright Boosts Instil Bio (TIL) Price Target Following Positive Data Release | TIL Stock News - GuruFocus
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago - GlobeNewswire
Instil Bio (TIL) Advances Clinical Trials for NSCLC Treatment | - GuruFocus
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in - GlobeNewswire
Finanzdaten der Instil Bio Inc-Aktie (TIL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.94%
2.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):